Biotherapeutics and biotherapy of surgical enteropathies

Digestive and Liver Disease

Volumn 34, Issue , 2002, Pages S87-S97

  Periti, P ^a   Tonelli, F ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biotherapeutics; Prebiotics; Probiotics; Saccharomyces boulardii

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; TINIDAZOLE; VANCOMYCIN;

ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG FECES LEVEL; DRUG SAFETY; ENTEROPATHY; FOOD; HUMAN; INGESTION; INTESTINE SURGERY; MAJOR CLINICAL STUDY; PRESCRIPTION; SACCHAROMYCES BOULARDII;

DIARRHEA; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS; SACCHAROMYCES;

EID: 0036743547     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(02)80174-8     Document Type: Article

References (97)

1. Periti P, Mazzei T. Antibiosi, probiosi, prebiosi ed omeostasi microbica intestinale: breve rassegna della letteratura. Farm Ter 1998;3/4:149-55.
2. Periti P, Capurso L. Componenti dietetiche non-nutrizionali ed omeostasi del microbiota intestinale. Farm Ter 1999;XVI:9-19.
3. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. J Am Med Ass 1996;275:870-6.
4. Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22.
5. Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud J-C, Matuchansky C. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 1999; 117:1043-50.
6. Periti P, Tonelli F. Attualità bioterapeutiche degli agenti probiotici. Ruolo del Saccharomyces boulardii. Farm Ter 2000;XVII:24-45.
7. Simmering R, Blaut M. Pro- and prebiotics - the tasty guardian angels? Appl Microbiol Biotechnol 2001;55:19-28.
8. Hamilton-Miller JMT. Living in the ‘post-antibiotic era’: could the use of probiotics be an effective strategy? Clin Microbiol Infect 1997;3:2-4.
9. Gibson GR. Probiotics and prebiotics - Notes from a session held at the 21st International Congress of Chemotherapy, Birmingham, UK, July 1999. Antibiotics Chemotherapy (Newsletter of the International Society of Chemotherapy) 2000;4:4-5.
10. Van der Waaij DJM, Berghuis JM, Lekkerkerk-van der Wees JEC. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg 1971;72:605-10.
11. Van der Waaij D. Colonization pattern of the digestive tract by potentially pathogenic micro-organisms: colonization-controlling mechanisms and consequences for antibiotic treatment. Infection 1983; 11 (Suppl 2):90-2.
12. Walker WA, Duffy LC. Diet and bacterial colonization: role of probiotics and prebiotics. J Nutr Biochem 1998;9:668-75.
13. Holzapfel WH, Haberer P, Snel J, Schillinger U, Huis in't Veld JHJ. Overview of gut flora and probiotics. Int J Food Microbiol 1998;41:85-101.
14. Roberfroid MB. Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr 1998;80(Suppl 2):S197-202.
15. McFarland LV. Biotherapeutic agents for Clostridium difficile-associated disease. In: Elmer GW, McFarland L, Surawicz C, editors. Biotherapeutic agents and infectious diseases. Totowa, NJ: Humana Press Inc.; 1999. p. 159-93.
16. Milner JA. Functional foods and health promotion. J Nutr 1999;129:S1395-7.
17. Hasler CM. The changing face of functional foods. J Am Cell Nutr 2000;19:S499-506.
18. Lee Y-K, Nomoto K, Salminen S, Gorbach SL. Handbook of probiotics. New York: John Wiley and Sons, inc.; 1999.
19. O’Sullivan GC. Probiotics. Br J Surg 2001;88:161-2.
20. Vandenplas Y. Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part I: bacteria. Clin Microbiol Infect 1999;5:299-307.
21. Vandenplas Y. Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part II: yeasts. Clin Microbiol Infect 1999;5:389-95.
22. McFarland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microbial Ecology Health Dis 1993;6:157-71.
23. Elmer GW, Moyer KA, Vega R. Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microecology Ther 1995;25:23-31.
24. Martin SW, Heatherington AC, Elmer GW. Pharmacokinetics of biotherapeutic agents. In: Elmer GW, McFarland L, Surawicz C, editors. Biotherapeutic agents and infectious diseases. Chapter 3. Totowa, NJ: Humana Press Inc.; 1999. p. 47-84.
25. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 1989;10:353-64.
26. Klein SM, Elmer GW, McFarland LV, Surawicx CM, Levy RH. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 1993; 10: 1615-9.
27. Elmer GW, Martin SW, Homer KL, McFarland LV, Levy RH. Survival of Saccharomyces boulardii in the gastrointestinal tract and interactions with dietary fiber. Personal Communication 1998.
28. Machado Caetano JA, Parames MT, Babo MJ, Santos A, Ferreira AB, Freitas AA, et al. Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. Int J Immunopharmacol 1986;8:245-59.
29. Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E, Immunity and probiotics. Immunol Today 1999;30:387-90.
30. Marteau P, Cellier C. Immunological effects of biotherapeutic agents. In: Elmer GW, McFarland L, Surawicz C, editors. Biotherapeutic agents and infectious diseases. Chap. 5. Totowa, NJ: Humana Press Inc.; 1999. p. 121-44.
31. Blum S, Delneste Y, Donnet A, Schiffrin EJ. The influence of probiotic organisms on the immune response. In: Gershwin ME, German JB, Keen CL, editors. Nutrition and immunology - principles and practice. Totowa, NJ: Humana Press Inc.; 2000. p. 451-5.
32. Nicod-Bertin L, Panouse-Perrin J. Propriétés activatrices de deux préparations de levures vis-à-vis du systéme complément humain. Rev Inst Pasteur Lyon 1985; 18:345-65.
33. Ducluzeau R, Bensaada M. Effect comparé de l’administration unique ou en continu de Saccharomyces boulardii sur l’établissement de diverses souches de Candida dans le tractus digestif de souris gnotoxéniques. Ann Microbiol 1982; 133:491-501.
34. Bergogne-Berezin E, Bornet M. In vitro antagonistic effect of Saccharomyces boulardii against bacteria involved in diarrhea in intensive-care-unit patient. Sci Alim 1986;6:63-73.
35. Berg R, Bernasconi P, Fowler D, Gautreux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis 1993;168:1314-8.
36. Czerucka D, Roux 1, Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 1994;106:65-72.
37. Dias RS, Bambirra EA, Silva ME, Nicoli JR. Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz J Med Biol Res 1995;28:323-5.
38. Vidon N, Huchet B, Rambaud JC. Influence de Saccharomyces boulardii sur la sécrétion jéjunale induite chez le rat par la toxine cholérique. Gastroenterol Clin Biol 1986; 10: 13-6.
39. Castagliuolo 1, Lamont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996;64:5225-32.
40. Pothoulakis C, Kelly CP, Joshi MA, Sao N, O'Keane CJ, Castagliuolo I, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993;104:1108-15.
41. Buts JP, De Keyser N, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endolulminal release of polyamines. Pediatr Res 1994;36:552-7.
42. Tutton PJ, Barkla DH. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells. Anticancer Res 1987;7:1-12.
43. Capano G, Bloch KJ, Carter EA, Dascoli JA, Schoenfeld D, Harmatz PR. Polyamines in human and rat milk influence intestinal cell growth in vitro. J Pediatr Gastroenterol Nutr 1998;27:281-6.
44. Vanderhoof JA, Kollman K, Goulet O. Saccharomyces boulardii does not stimulate mucosal hyperplasia following intestinal resection in the rat. J Pediatr Gastroenterol Nutr 1998;26:567.
45. Zaouche A, Loukil C, De La Gauisie P, Peuchmaur M, Macry J, Fitoussi F, et al. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation and intestinal adaptation after small bowel resection in growing rats. Scand J gastroenterol 2000;35:160-5.
46. Buts J-P, De Keyser N, Marandi S, hermans D, Sokal EM, Chae YL, et al. Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut 1999;45:89-96.
47. Bergogne-Bérézin E. Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents 2000; 16:521-6.
48. Adam P. Essais cliniques controlés en double insu de l'ultra-levure lyophilisée (étude multicentrique par 25 médecins de 388 cas). Médecine et Chirurgie Digestive 1976;5:401-6.
49. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981-8.
50. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Ass 1994;271:1913-8.
51. Högenauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998;27:702-10.
52. Tempé JD, Steidel AL, Bléhaut H, Hasselman M, Lutun Ph, Maurier F. Prévention par Saccharomyces boulardii des diarrhées de l'alimentation entérale à débit continu. Sem Hop Paris 1983;59:1409-12.
53. Schlotterer M, Bernasconi P, Lebreton F, Wasserman D. Intérêt de Saccharomyces boulardii dans la tolérance digestive de la nutrition entérale à débit continu chez le brûlé. Nutr Clin Metab 1987;1:31-4.
54. Bleichner G, Bléhaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Intensive Care Med 1997;23:517-23.
55. Cetina-Sauri G, Sierra Basto G. Evaluation thérapeutique de Saccharomyces boulardii chez des enfants souffrant de diarrhée aiguë. Ann Pediatr 1994;41:397-400.
56. Höchter W, Chase D, Hagenhoff G. Saccharomyces boulardii in acute adult diarrhoea. Münch Med Wochenschr 1990;132:188-92.
57. Castaneda C. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially due to giardiasis. Rev Mexicana Puericultura Pediatr 1995;2:120-6.
58. Saint-Marc T, Bléhaut H, Musial Ch, Touraine JL. Diarrhöen im Zusammenhang mit AIDS (Doppelblindstudie mit Saccharomyces boulardii). Sem Hosp Paris 1995;71:735-41.
59. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hop Epidermiol 1999;20:43-50.
60. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan E. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blind trial. Clin Infect Dis 1997;24:324-33.
61. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea. Arch Intem Med 2001;161:525-33.
62. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis 1993;269:71-5.
63. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melchee SA, et al. Prevention of β-lactam-associated diarrhea by Saccharomycis boulardii compared with placebo. Am J Gastroenterol 1995;90:439-48.
64. Vogel LC. Antibiotic-induced diarrhea. Orthop Nurs 1995;14:38-41.
65. Toothaker RD, Elmer GW. Prevention of clindamycin-induced mortality in hamsters by Sacharomyces boulardii. Antimicrob Agents Chemother 1984;26:552-6.
66. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-7.
67. Rowlands BJ, Gardiner KR. Nutritional modulation of gut inflammation. Proc Nutr Society 1998;57:395-401.
68. MacFie J, O'Boyle C, Mitchell CJ, Buckley PM, Johnstone D, Sudworth P. Gut origin of sepsis: a prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut 1999;45:223-8.
69. Rowlands BJ, Vonn Soong C, Gardiner KR. The gastrointestinal tract as a barrier in sepsis. Br Med Bull 1999;55:196-211.
70. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi S, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
71. Ouellette AJ, Selsted ME. Paneth cell defensins: endogenous peptide components of intestinal host defense. Faseb J 1996;10:1280-9.
72. Cunningham-Rundles S, Lin DH. Nutrition and the immune system of the gut. Nutrition 1998;14:573-9.
73. Blum S, Alvarez S, Haller D, Perez P, Schiffrin EJ. Intestinal microflora and the interaction with immunocompetent cells. Antonie van Leeuwenhoek 1999;76:199-205.
74. Brook I. Bacterial interference. Crit Rev Microbiol 1999;25:155-72.
75. Kollaritsch HH, Kemsner P, Wiedermann G, Scheiner O. Prevention of traveller’s diarrhoea. Comparison of different non-antibiotic preparations. Travel Med Int 1989;23:9-17.
76. Kirchelle A, Frühwein N, Toburen D. Behandlung der persistierenden Diarhöe mit S. boulardii bei Reiserückkehren. Fortschr Med 1996;144:136-40.
77. Sadoun-Journo E, Gaillard JL, Belhaut G, Goulet O, Bernasconi P, Ricour C. Grêle court dysfonctionnel (GCD) compliqué de pullalation bactérienne chez l'enfant: effet de Saccharomyces boulardii (SB). Gastroenterol Clin Biol 1994;18:101-3.
78. Plein J, Hotz J. Therapeutic effect of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea, a pilot study. Z Gastroenterol 1993;31:129-34.
79. Tetteroo GWM, Wagenzoort JHT, Bruining HA. Role of selective decontamination in surgery. Br J Surg 1992;79:300-4.
80. Donnel SC, Taylor N, van Saene HKF, Pierro A, Lloyd DA. Nutritional implications of gut overgrowth and selective decontamination of the digestive tract. Proc Nutr Society 1998;57:381-7.
81. Beier-Holgersen R, Boesby S. Influence of postoperative enteral nutrition on postsurgical infections. Gut 1996;39:833-5.
82. McFarland LV, Elmer GW. Pharmaceutical probiotics for the treatment of anaerobic and other infections. Anaerobe 1997;3:73-8.
83. Caplan MS, Jilling T. Neonatal necrotizing enterocolitis: possible role of probiotic supplementation. J Ped Gastroenterol Nutr 2000;30:S18-22.
84. Kirjavainene PV, Apostolou E, Salminen SJ, Isolauri E. New aspects of probiotics - a novel approach in the management of food allergy. Allergy 1999;54:909-15.
85. Periti P, Tonelli F, Capurso L, Nicoletti P. Managing Helicobacter pylori infection in the New Millennium: a review. J Chemother 1999;11(Suppl 4):3-55.
86. Armuzzi A, Cremonini F, Ojetti V, Bartolozzi F, Canducci F, Candelli M, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001a;63:1-7.
87. Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001b;15:163-9.
88. Adams MR, Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol 1995;27:263-4.
89. Donohe DC, Salminen S. Safety of probiotic bacteria. Asia Pac J Clin 1996;5:25-8.
90. Aguirre M, Collins K. Lactic acid bacteria and human clinical infections. J Appl Bacteriol 1993;75:95-107.
91. Gasser F. Safety of lactic acid bacteria and their occurrence in human clinical infections. Bull Inst Pasteur 1994;92:45-67.
92. Saxelin M, Rautelin H, Salminen S, Mäkelä P.The safety of commercial products with viable Lactobacillus strains. Infect Dis Clin Pract 1996;5:331-5.
93. Goldin BR. Health benefits of probiotics. Br J Nutt 1998;80(Suppl 2): S203-7.
94. Surawicz CM, McFarland LV. Risks of biotherapeutic agents. In: Elmer GW, McFarland L, Surawicz C, editors. Biotherapeutic agents and infectious diseases. Totowa, NJ: Humana Press Inc.; 1999. p. 263-8.
95. Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000;19:16-20.
96. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;9:499-511.
97. Kralovicova. K, Spanik S, Oravcova E, Mraeva M, Morova E, Guclikova V, et al. Fungemia in cancer patients undergoing chemotherapy versus surgery: risk factors, etiology and outcome. Scand J Infect Dis 1997;29:301-4.